INTRODUCTION
Human ESCRT-I (endosomal sorting complex required for transport-I) is a multiprotein complex that helps sort membrane proteins into vesicles that bud into late endosomal compartments called multivesicular bodies (MVB) (Gill et al., 2007b; Gruenberg and Stenmark, 2004; Hurley and Emr, 2006) . ESCRT-I also mediates the budding of HIV-1 and other enveloped RNA viruses (Bieniasz, 2006; Demirov and Freed, 2004; Morita and Sundquist, 2004) . Hence, ESCRT-I plays essential roles in several significant biological processes, including the release of human pathogens and the essential downregulation of cell surface receptors targeted for lysosomal degradation via MVB vesicles.
Under steady state conditions, ESCRT-I is distributed throughout the cytoplasm, but is transiently recruited to sites of MVB vesicle and virus budding (Katzmann et al., 2001; Martin-Serrano et al., 2001; Welsch et al., 2006) . ESCRT-I is recruited to function in HIV-1 budding via direct interactions with the PTAP ''late domain'' sequence located within the p6 region of the viral Gag polypeptide. Gag is the major viral structural protein and has the intrinsic ability to bind membranes and assemble into spherical particles, but requires the ESCRT-I interaction to accomplish the membrane fission required for efficient virion release. Virion budding initiates viral maturation, a stepwise process that involves (1) activation of the viral protease; (2) proteolytic cleavage of Gag at a series of different sites to liberate the mature MA, CA, and NC proteins; and (3) major structural rearrangements involving condensation of the NC-RNA complex and assembly of CA into the conical capsid that surrounds the NC-RNA complex.
In the endosomal pathway, ESCRT-I can be recruited to function in MVB vesicle formation through direct interactions with the upstream HRS/Vps27p protein complex (Bache et al., 2003; Katzmann et al., 2003; Lu et al., 2003; Pornillos et al., 2003) . Once localized to the membrane, ESCRT-I can bind ubiquitylated protein cargoes and recruit downstream effector complexes such as ESCRT-II and ESCRT-III that help mediate protein sorting and vesicle formation. The assembled ESCRT complexes are then recycled by the action of the VPS4 ATPases, the only known enzymes in the pathway (Babst et al., 1998) .
Human and yeast ESCRT-I complexes share at least three homologous subunits, termed TSG101/Vps23p, VPS28/Vps28p and VPS37/Vps37p. Structural and biochemical analyses have revealed that the yeast Vps23p, Vps28p, and Vps37p subunits form a 1:1:1 ternary complex in which conserved segments from each subunit coassemble into a six helix bundle (Chu et al., 2006; Gill et al., 2007a; Kostelansky et al., 2006; Teo et al., 2006) . Each subunit contributes a helical hairpin, which associate side-to-side along their long axes with the Vps23p hairpin in the center. Outside of the helical bundle, the ESCRT-I subunits display a series of ''effector'' domains that interact with other protein binding partners. For example, Vps23p/TSG101 has a predicated coiled-coil element immediately upstream of the core hairpin that has been implicated in protein oligomerization (Chu et al., 2006; Martin-Serrano et al., 2003) and an N-terminal UEV domain that binds both ubiquitin (Garrus et al., 2001; Katzmann et al., 2001; Sundquist et al., 2004; Teo et al., 2004) and proline-rich elements such as the P(S/T)AP elements in HIV-1 p6
Gag and HRS/Vps27p (Pornillos et al., 2002) . The basic architecture of mammalian ESCRT-I appears to be similar to that of yeast ESCRT-I because the TSG101/Vps23p, VPS28/Vps28p, and VPS37/Vps37p subunits have common domain organizations and related sequences. Mammalian ESCRT-I complexes exhibit greater complexity, however, as mammalian cells express four different, but related, VPS37 subunits (termed VPS37A-D) (Bache et al., 2004; Eastman et al., 2005; Stuchell et al., 2004) . Each different VPS37 protein contains a region of 150 amino acids that includes the minimal TSG101-binding element and is related in sequence to yeast Vps37p. The different mammalian VPS37 proteins diverge significantly outside of this conserved region, however, which may allow them to interact with distinct cellular binding partners.
Recently, several groups have characterized a fourth subunit of the yeast ESCRT-I complex, termed Mvb12p (Chu et al., 2006; Curtiss et al., 2007; Gill et al., 2007a; Oestreich et al., 2007) . Metazoan homologs of Mvb12p have not yet been identified, although Chu et al. have noted weak sequence similarities between Mvb12p and human apolipoprotein O (Chu et al., 2006) . As part of our continuing effort to characterize human ESCRT-I and its role in HIV-1 budding and assembly, we have searched for cellular proteins that bind ESCRT-I. Here, we report the identification and characterization of a fourth class of proteins that function as stable, constitutive subunits of human ESCRT-I and are required for efficient HIV-1 assembly and infectivity.
RESULTS

Identification of MVB12A as a Binding Partner for the Human ESCRT-I Complex
The six known human ESCRT-I subunits (One-STrEP-FLAG (OSF)-TSG101, VPS28, and VPS37A-D) were simultaneously coexpressed in 293T cells to create ''baits'' that could be used to identify ESCRT-I binding proteins. The resulting mixture of ESCRT-I complexes was affinity purified on a Strep-Tactin matrix, which captured TSG101 and stable binding partners. Bound proteins were analyzed by SDS-PAGE ( Figure 1A , lane 2), and the ESCRT-I subunits were identified by comparison to known standards. As expected, the tagged TSG101 subunit and the five other overexpressed ESCRT-I subunits were substantially enriched by this procedure. In addition, a seventh endogenous protein with a molecular mass of 30 KDa reproducibly copurified with the ESCRT-I complexes (denoted ''?'' in Figure 1A , lane 2). This protein was identified by in-gel trypsin digestion and mass spectrometry analyses, which produced eight different peptides, matching those predicted for NCBI protein NP_612410 (273 residues, 41% coverage, see Table S1 ), which is hereafter called MVB12A (multivesicular body subunit 12A). Database and literature searches revealed that MVB12A was a previously uncharacterized protein of unknown function and also identified a second related human protein of 319 residues (MVB12B) that shared 30% sequence identity with MVB12A (NCBI protein NP_258257, Figure S1 ).
In addition to MVB12A, a series of other endogenous proteins copurified with the OSF-TSG101-VPS37-VPS28 complexes, albeit at lower levels. To test whether endogenous MVB12B was one of these copurifying proteins, a gel section spanning the expected mass of MVB12B (30-40 KDa) was excised and analyzed by trypsin digestion and mass spectrometry. This experiment confirmed the presence of MVB12B in the affinity purified mixture (4 peptides, 38% coverage, Table S1 ). Hence, both MVB12A and MVB12B proteins were expressed in 293T cells, and both coaffinity purified with overexpressed ESCRT-I complexes, indicating that these two proteins might be ESCRT-I subunits or binding partners.
In related experiments, Strep-tagged versions of each of the different ESCRT-I proteins were also expressed singly, and trypsin digestion and mass spectrometry were again used to identify other ESCRT-I subunits that copurified by Strep-Tactin affinity chromatography (Table  S1 ). Pairwise interactions between MVB12 proteins and other ESCRT-I subunits were observed 21 different times in these experiments, further confirming that MVB12A and MVB12B associate with the other ESCRT-I subunits in vivo. In contrast, apolipoprotein O, a previously proposed candidate for the mammalian homolog of yeast Mvb12p (Chu et al., 2006) , was not detected in any of our proteomics studies.
MVB12A Binds All Possible Human ESCRT-I Complexes
To test whether MVB12A could form stable stoichiometric complexes with the other three ESCRT-I subunits, Myc-MVB12A was co-overexpressed together with OSF-TSG101, VPS28, and VPS37B, and complexes were again affinity purified on a Strep-Tactin matrix. As shown in Figure 1B , equivalent levels of VPS28, VPS37B, and MVB12A copurified with OSF-TSG101 (lane 2), but did not bind a control matrix (lane 1), indicating that the interactions were specific and were mediated by TSG101. In reciprocal experiments, equivalent levels of Myc-TSG101, VPS28, and Vps37B copurified with OSF-MVB12A (lane 4), and again did not bind the matrix control (lane 3). Thus, MVB12A forms stable quaternary complexes with TGS101, VPS28, and VPS37B in human cells. Analogous experiments performed for MVB12B showed that TSG101, VPS28, and VPS37B also formed stable complexes with MVB12B ( Figure S2A , lanes 2 and 4) without background binding to control matrices (lanes 1 and 3).
We also tested the possibility that specific VPS37 subunits might uniquely pair with specific MVB12 subunits. This was not the case, however, as all four known human VPS37 subunits (VPS37A-D) formed stable quaternary complexes with TSG101-VPS28-MVB12A ( Figure 1C , lanes 1-4) and with TSG101-VPS28-MVB12B ( Figure S2B ). Thus, human cells express multiple paralogs of both VPS37 and MVB12, and all 8 possible combinations of human ESCRT-I subunits assemble into stable complexes in human cells.
MVB12A Binds ESCRT-I through Its Conserved C Terminus
Deletion analyses were used to map the ESCRT-I binding site(s) on the MVB12 proteins. A summary of the different MVB12 constructs employed in these studies is provided in Figure S3 . As shown in Figure 2A , an MVB12A fragment lacking the final 40 residues (MVB12A 1-233 ) formed a stable complex with the other three ESCRT-I proteins (lane 3), whereas a construct lacking the final 82 residues (MVB12A ) did not (lane 4). Conversely, an MVB12A fragment consisting of only the final 82 residues ) formed a stable ESCRT-I complex (lane 5), demonstrating that the C-terminal region of MVB12A was necessary and sufficient for ESCRT-I binding. The interaction site could not be subdivided further, however, as two nonoverlapping C-terminal fragments of MVB12A ) both bound ESCRT-I (lanes 6 and 7). Hence, MVB12A must contact ESCRT-I through at least two adjacent sites, one located within residues 192-233 and a second within residues 234-273 (termed ESCRT-I-binding boxes 1 and 2, abbreviated EBB1 and EBB2). An alignment of metazoan MVB12 proteins indicates that the sequence corresponding to MVB12A residues 192-233 (EBB1) is the most highly conserved region of the protein ( Figure S1 ), and our mapping experiments indicate that this sequence conservation reflects a conserved ESCRT-I binding function.
MVB12B exhibits additional complexity in that two different splice isoforms of the protein have been identified (NCBI FAM125B, GeneID no. 89853). The longer isoform 1 (MVB12B 1-319 ) contains both EBB1 and EBB2, whereas the shorter isoform 2 (MVB12B 1-221 ) does not. Binding experiments confirmed the expectation that MVB12B 1-319 bound ESCRT-I, whereas MVB12B 1-221 did not (Figure 2A , compare lanes 9 and 10). Furthermore, a fragment of MVB12B corresponding to the EBB1 alone (MVB12B 227-271 ) again bound ESCRT-I (Figure 2A , lane 11), demonstrating that MVB12B EBB1 was also an ESCRT-I binding module. Thus, both MVB12A and MVB12B bind the ESCRT-I complex through conserved C-terminal ESCRT-I Binding Boxes, whereas a shorter MVB12B isoform missing this region does not bind ESCRT-I.
MVB12A and MVB12B Bind the TSG101-VPS37 Binary Complex
To map the binding requirements on the ESCRT-I side of the interaction, we first tested whether MVB12A could bind TSG101, VPS37B, or VPS28 alone. As shown in Figure 2B , Myc-MVB12A did not copurify at stoichiometric levels with any of the four isolated OSF-tagged ESCRT-I subunits (upper panel, lanes 2-4). We next tested whether MVB12A could bind any of the possible binary complexes of other ESCRT-I subunits (lanes 5-10). These experiments revealed that MVB12A bound TSG101-VPS37B subcomplexes (lanes 7 and 8), but none of the other possible ESCRT-I binary complexes (lanes 5, 6, 9, and 10). Control experiments behaved as expected in that MVB12A bound the ternary TSG101-VPS28-VPS37 These experiments imply that a binary TSG101-VPS37 complex is required to create a high affinity MVB12A binding site.
Deletion analyses were performed to map the regions of TSG101 and VPS37B required for MVB12A binding. As shown in Figure 2C , MVB12A binds the final 159 residues of TSG101 (TSG101 231-390 ), which spans the ESCRT-I core (lanes 3 and 8). Similarly, MVB12A binding mapped to the N-terminal half of VPS37B (VPS37B 1-160 , lanes 6 and 8), which again corresponds to the most conserved region of VPS37 and includes the minimal TSG101 binding site. Thus, MVB12A binds the regions of TSG101 and VPS37 that form the ESCRT-I core (summarized in Figure 2D ).
MVB12 Proteins Are Integral Components of Native ESCRT-I Complexes
Endogenous mammalian ESCRT-I complexes reportedly elute from gel filtration columns with an apparent molecular weight of 300-350 KDa (Babst et al., 2000; Stuchell et al., 2004) . This observation is recapitulated in Figure 3 (panel 1), where anti-TSG101 antibodies were used to follow the gel filtration mobility of native ESCRT-I complexes from crude soluble cell lysates. The apparent molecular weight of human ESCRT-I was estimated to be 270-280 KDa on this calibrated gel filtration column. To test whether endogenous MVB12A is also a constitutive component of ESCRT-I in human cells, anti-MVB12A antibodies were raised and used to track the gel filtration mobility of MVB12A. As shown in panel 2, essentially all of the native MVB12A protein in the extract also precisely coeluted with TSG101, as well as other ESCRT-I subunits (data not shown). This experiment indicates that endogenous MVB12A is stably associated with ESCRT-I.
Our attempts to perform analogous experiments with MVB12B were unsuccessful because our anti-MVB12B antibodies did not detect the endogenous protein. Nevertheless, the gel filtration experiments shown in Figure 3 demonstrate that when TSG101, VPS28, and VPS37B were co-overexpressed with either MVB12A (panel 4) or MVB12B (panel 5), the MVB12 proteins again eluted from gel filtration columns in complexes with apparent molecular weights of 270 KDa. These observations indicate that both MVB12 paralogs quantitatively associate with the other ESCRT-I subunits in cells. Moreover, these exogenous ESCRT-I complexes exhibited the same gel filtration mobilities as native, endogenous ESCRT-I complexes (compare panels 1 and 2 to 4 and 5).
We also tested whether gel filtration mobility could be used to distinguish ESCRT-I complexes that lacked MVB12 subunits by examining the mobility of ESCRT-I complexes from 293T cells in which only TSG101, VPS37B, and VPS28 were highly overexpressed. Although endogenous ESCRT-I subunits were still present in these cells, the endogenous MVB12 subunits were limiting, and the bulk of the tagged TSG101 in the cell was therefore present in TSG101-VPS37B-VPS28 ternary complexes. The apparent molecular weight of these ternary complexes (MW app 210 KDa) was lower than that of the quaternary ESCRT-I complexes, as assessed by following the elution of TSG101 (panel 3) or other ESCRT-I subunits, (data not shown). The shift was modest (MW app 60 KDa), however, and the TSG101 elution peak was broadened, possibly owing to the presence of both ternary and quaternary complexes, self-association of the ternary complex, or overexpression effects. Importantly, the gel filtration mobility of native ESCRT-I complexes (panels 1 and 2) matched that of the quaternary TSG101-VPS37-VPS28/MVB12 complexes (panels 4 and 5) rather than the ternary TSG101-VPS37-VPS28 complexes (panel 3). This experiment indicates that most (and perhaps all) endogenous cellular ESCRT-I complexes contain MVB12 subunits, although we cannot rule out the possibility that a minor pool of endogenous ESCRT-I complexes may lack MVB12 subunits owing to the limited resolution of the gel filtration experiment.
Recombinant ESCRT-I Complexes Bind HIV-1 p6
Gag and HRS As discussed earlier, pure intact recombinant ESCRT-I complexes from higher organisms have not been described previously, both because MVB12 subunits had not been identified and because the proline-rich, N-terminal half of TSG101/Vps23p is difficult to express in E. coli. We therefore tested whether the mammalian coexpression system could be used to generate stable, full-length recombinant ESCRT-I complexes for use in biochemical and structural studies. As shown in Figure 4A (left panel), milligram quantities of pure recombinant human ESCRT-I could be generated by co-overexpressing all of the subunits in 293T cells, followed by affinity purification on Strep-Tactin agarose and gel filtration chromatography.
ESCRT-I is recruited to sites of HIV-1 budding by the viral p6
Gag protein, and we therefore tested whether this interaction could be recapitulated in vitro. As shown in Figure 4A (middle panel), purified ESCRT-I bound wildtype GST-p6 Gag protein immobilized on glutathione agarose, as detected in a western blot using anti-FLAG (TSG101) antibodies (lane 2). This interaction appeared to be specific because TSG101/ESCRT-I did not bind to a control GST matrix (lane 1) or to an immobilized GSTp6 Gag protein with a point mutation in the key interacting proline residue in the TSG101 binding site (p6 Gag P10A, lane 3). In cells, ESCRT-I can be recruited to sites of MVB vesicle formation by the HRS complex. This interaction could also be recapitulated in vitro using pure recombinant ESCRT-I and purified HRS, and the interaction was again specific ( Figure 4A, right panel) . Thus, the ESCRT-I interactions with p6 Gag and HRS can be recapitulated with pure recombinant proteins.
Soluble, Endogenous Human ESCRT-I Is a 1:1:1:1 Heterotetramer Several lines of evidence suggest that TSG101 and ESCRT-I have a propensity to self-associate in cells, and it has been proposed that Mvb12p stabilizes a trimeric (or possibly dimeric) form of yeast ESCRT-I (Chu et al., 2006) . However, biophysical studies of pure recombinant yeast ESCRT-I complexes indicate that recombinant Vps23p (TSG101), Vps28p, Vps37p, and Mvb12p form a stable, 1:1:1:1 complex in solution (Gill et al., 2007a) . To date, there have been no reports of the solution mass and stoichiometry of mammalian ESCRT-I complexes.
Equilibrium sedimentation experiments were therefore performed to determine the solution mass of purified ESCRT-I complexes. The predominant form of affinity purified, recombinant ESCRT-I eluted from a gel filtration column with a MW app 280-270 KDa (see Figure 3) . A small amount of recombinant ESCRT-I also eluted as a minor peak of MW app 570 KDa (note that this minor species is not visible in panel 1, and was not detected for endogenous ESCRT-I). Analytical equilibrium sedimentation data for the major recombinant ESCRT-I complex matched that expected for a 1:1:1:1 complex of TSG101:VPS28:VPS37B:MVB12A ( Figure 4B , black curve), but not for a 2:2:2:2 ''dimeric'' (red) or higher order complexes. In contrast, the minor ESCRT-I species was successfully modeled as a 2:2:2:2 ''dimer'' (Figure S4) . Hence, the major soluble cellular ESCRT-I species contains a single copy of each of the four different subunits. Importantly, the gel filtration mobility of endogenous ESCRT-I complexes corresponded well to the mobility of the recombinant 1:1:1:1 ESCRT-I complex (compare panel 1 to panels 4 and 5 in Figure 3) . We therefore conclude that soluble endogenous human ESCRT-I complexes extracted from cells contain single copies of TSG101, VPS37, VPS28, and MVB12. 
MVB12A Is Recruited to Class E Compartments as a Component of ESCRT-I
Under steady state conditions, ESCRT-I complexes are transiently recruited to endosomal membranes, where they function in MVB vesicle formation and are subsequently released by the action of the VPS4 ATPases (Babst et al., 1997 (Babst et al., , 1998 . Hence, ESCRT-I complexes become trapped on aberrant endosomal compartments (termed class E compartments) in the presence of dominant negative VPS4 proteins that lack ATPase activity. This system was therefore used to test whether MVB12A was recruited to Class E compartments as a component of ESCRT-I. As shown in Figure 5A , epitope tagged WT MVB12A, TSG101, and WT GFP-VPS4A were all distributed throughout the cell when the three wild-type proteins were co-overexpressed, together with untagged versions of the other ESCRT-I subunits (upper row). MVB12A also concentrated on centrosomes (see Figure S5 ). In contrast, all three proteins became concentrated on punctate class E compartments when the overexpressed VPS4A protein lacked ATP-binding activity (VPS4A K173Q; middle row). This marked redistribution of MVB12A correlated with the ability of MVB12A to bind ESCRT-I, because a truncated MVB12A protein that lacked the ESCRT-I binding site (MVB12A ) failed to redistribute to class E compartments (bottom row). These observations were quantified by determining the degree of overlap between the dominant-negative VPS4A K173Q protein and the other proteins. As shown in Figure 5B , most of the WT MVB12A in the cell colocalized with VPS4A K173Q (69 ± 11% colocalization), as did most of the WT TSG101 (70 ± 14% colocalization). In contrast, almost none of the truncated MVB12A 1-191 protein colocalized with VPS4A K173Q (3.2 ± 1.6%) even though TSG101-VPS4A K173Q colocalization was not significantly affected (60 ± 14%). These experiments indicate that MVB12A is recruited to endosomal membranes through its conserved C-terminal ESCRT-I binding region and is then released from the membrane by the activity of the VPS4 ATPase.
HIV-1 Infectivity, but Not Release, Is Reduced upon MVB12 Depletion ESCRT-I facilitates HIV-1 budding, and it was therefore of interest to determine whether depletion of MVB12A and MVB12B affects the late stages of HIV-1 replication. As shown in Figure 6A , we identified two different siRNAs that reduced the endogenous MVB12 protein to nearly undetectable levels (upper panel). Analogous experiments could not be performed for MVB12B, however, owing to our inability to detect the endogenous protein in western blots. Nevertheless, we did identify two different siRNAs that could efficiently deplete exogenously expressed Myc-MVB12B (lower panel). As shown in Figure 6B , different combinations of the anti-MVB12 siRNA oligonucleotides reduced infectious viral titers 2-5 fold. These experiments indicate that normal cellular levels of MVB12A and MVB12B are required for full HIV-1 infectivity.
Somewhat surprisingly, the phenotypic consequences of MVB12 depletion differed in several respects from depletion of TSG101 (positive control, last lane). First, MVB12 depletion did not reduce viral infectivity to the same extent as TSG101 depletion (42-fold reduction), suggesting that the MVB12 subunits of ESCRT-I may not play as central a role in HIV-1 budding as the TSG101 subunit. Second, MVB12 protein depletion did not measurably reduce HIV-1 particle production, as judged by western blotting of particle-associated CA and MA proteins released into culture supernatants ( Figure 6B , middle panel). Thus, the reduction in viral infectivity seen upon depletion of MVB12 proteins was not explained by a proportional reduction in virus budding.
EM analyses were therefore performed to test whether virions released in the absence of MVB12 proteins exhibited an observable morphological defect that might explain their reduced infectivity. As expected, HIV-1 particles released from wild-type cells frequently exhibited conical capsids, which is the hallmark of mature virions. As summarized in Figure 6C , mature HIV-1 capsids were observed in just over half of the control particles examined (52%). In contrast, depletion of either MVB12A or MVB12B reduced the frequency of mature HIV-1 particles by approximately 2-fold (29% and 27%, respectively) as compared to the wild-type control, and instead resulted in the production of an abnormally large number of aberrant particles. These particles were described as ''amorphous'' because the virion interiors were highly electron-dense throughout and lacked clearly defined internal structures (see Figure 6C , lower right panel). Amorphous particles accounted for only about 10% of the virions produced from wild-type cells, but much greater percentages of virions produced from MVB12A or MVB12B-depleted cells (29% and 47%, respectively). Hence, the reduced viral infectivity observed upon MVB12 depletion correlated with reduced production of mature virions and increased production of abnormal virions. Although we do not know what causes the aberrant virion interiors to appear so amorphous, we speculate that additional cellular proteins may be packaged within these particles, thereby increasing their density and obscuring the visualization of normal internal structures. This is suggested in the ''gradient'' of amorphous particle morphologies shown in Figure 6C , where internal core structures appear evident beneath the obscuring density within the lightest particles.
MVB12 Overexpression Reduces Virus Release, Gag Processing, and Viral Infectivity
Previous studies have established that overexpression of TSG101 (and TSG101 fragments) dominantly inhibits HIV-1 release and infectivity, presumably by altering the stoichiometry and/or activity of endogenous ESCRT-I complexes ( Figure 7A , compare lanes 1 and 6) (ShehuXhilaga et al., 2004) . As shown in Figure 7B , TSG101 overexpression induced a ''late domain'' phenotype in which assembling particles frequently remained tethered to the cell through membrane stalks. The interiors of these tethered particles were frequently abnormally dense and amorphous, which was reminiscent of the ''amorphorous'' phenotypes observed in virions produced from MVB12-depleted cells. Overexpression of both MVB12A and MVB12B also strongly inhibited HIV-1 infectivity (12-and 15-fold, respectively, Figure 7A left panel) with parallel reductions in virion release ( Figure 7A, right panel) . These reductions in virus release and infectivity were at least partially relieved, however, when the overexpressed MVB12A and MVB12B proteins lacked C-terminal ESCRT-I-binding boxes (compare lanes 2 to 3 and lanes 4 to 5), indicating that ESCRT-I-binding activity was required for full inhibition.
Once again, the phenotype of the HIV-1 assembly block induced by MVB12 overexpression was unusual in several respects. First, overexpression of MVB12A or MVB12B proteins reduced the levels of intact Gag polyproteins in producer cells only slightly (to 71 ± 8% of control for MVB12A), but dramatically reduced the accumulation of the intracellular MA and CA proteolytic processing products (to 11 ± 3% of control for MVB12A, see Figure 7A , right middle panel and figure caption). In spite of the strong reduction in particle release caused by MVB12 overexpression, however, the particles that were released had fully processed MA and CA proteins, indicating that Gag was processed in those particles that escaped the cell. EM analyses of the cell-associated viral particles produced in the presence of high levels of MVB12A revealed an additional assembly/budding defect. As shown in Figure 7B , viral particles produced in cells that overexpressed MVB12A frequently remained cell-associated. Unlike the case of TSG101 overexpression, however, most of these virions were not directly connected to the cell membrane, though they were frequently tethered to one another (and perhaps ultimately to the plasma membrane) through continuous lipid bridges. The tethered virions lacked mature conical capsids, and bore some resemblance to immature viral particles, but with less well-delineated Gag shells.
Mutation of MVB12A Phosphorylation Sites Partially
Relieves the Overexpression Block Endogenous MVB12A and MVB12B proteins frequently exhibited multiple banding patterns on SDS-PAGE gels suggestive of protein phosphorylation. Consistent with this observation, multiple threonine and serine phosphorylation sites in both MVB12A and MVB12B were identified by mass spectrometry ( Figure 7C , Table S2 , and Figure S6 ). To begin to test whether MVB12 phosphorylation was functionally important, we created two different expression constructs for mutant MVB12A proteins that lacked phosphorylation sites. The MVB12A 5A construct had alanine mutations in place of the five confirmed MVB12A phosphorylation sites, and the MVB12A 9A construct had four additional mutations that corresponded to mapped phosphorylation sites in MVB12B ( Figure 7C , lower two panels). Both mutant MVB12A proteins expressed well ( Figure 7D , lower right panel) and formed stable ESCRT-I complexes (data not shown), indicating that the mutations did not grossly alter MVB12A folding or ESCRT-I association. Nevertheless, the mutations attenuated the ability of overexpressed MVB12A to block HIV-1 infectivity ( Figure 7D , left panel), virion release (upper right panel), and Gag processing (middle right panel). Thus, MVB12A phosphorylation is not required for ESCRT-I complex formation, but is required for efficient MVB12A-mediated dominant inhibition of HIV-1 release and infectivity. Importantly, this is also the first indication that kinases (and perhaps also phosphatases) are involved in the ESCRT pathway.
DISCUSSION
Our studies reveal that MVB12 proteins are previously unidentified subunits of human ESCRT-I. Closely related MVB12 orthologs are conserved across metazoa, and vertebrates express two distinct, but related, MVB12 paralogs (MVB12A and MVB12B). Two other ESCRT-I subunits, TSG101 and VPS28, lack obvious paralogs, whereas mammals express four distinct, but related, VPS37 proteins from different genes (VPS37A-D). Soluble ESCRT-I complexes contain single copies of each of the four different subunit types (TSG101, VPS28, VPS37, and MVB12). Hence, the different known VPS37 and MVB12 paralogs can combine to produce up to eight different ESCRT-I variants, and we find that all possible combinations can form stable complexes in cells. Human cells also appear to express (1) two alternative VPS28 transcripts with different C-termini, one of which has a TSG101-binding PSAP motif (Gill et al., 2007a; MartinSerrano, personal communication) , and (2) a truncated splice isoform of MVB12B that lacks ESCRT-I binding activity. Thus, human ESCRT-I is best described as a heterogeneous family of related complexes. It is reasonable to expect that the different ESCRT-I isoforms will perform distinct, but possibly overlapping, functions. Obvious possible ways in which the different ESCRT-I isoforms could vary include expression patterns, cellular localization, cargo selection, biological functions, and/or mechanisms of regulation.
Yeast Mvb12p (12 KDa) is much smaller than both MVB12A (29 KDa) and MVB12B isoform I (36 KDa), and there are no significant regions of sequence similarity. Nevertheless, we believe that the human MVB12 proteins are the functional orthologs of yeast Mvb12p, as both the yeast and human proteins function as stable fourth subunits of ESCRT-I. Moreover, both Mvb12p and MVB12 bind the ESCRT-I core region, although one group has reported that Mvb12p binds Vps23p/TSG101 (Chu et al., 2006) , whereas another reported that it binds Vps37p (Curtiss et al., 2007) . This behavior seems consistent with our observations that (1) the binary TSG101/VPS37 complex forms the minimal binding site for human MVB12 proteins, implying that they may contact both TSG101 and VPS37, and (2) at least two different regions of the MVB12 proteins contact ESCRT-I. Moreover, although the precise functions of both Mvb12p and MVB12 proteins remain to be established, Mvb12p knockouts exhibit attenuated and unusual phenotypes as compared to knockouts of the other yeast ESCRT-I subunits, suggesting that Mvb12p may play a functionally unique or regulatory role in yeast ESCRT-I function (Chu et al., 2006; Curtiss et al., 2007; Oestreich et al., 2007) . Similarly, HIV-1 release and infectivity are less severely blocked by MVB12 depletion than by TSG101 depletion, and there are also significant phenotypic differences between the two conditions. Finally, while our manuscript was under review, Hurley and colleagues reported the crystal structure of the heterotetrameric yeast ESCRT-I core complex, which revealed a highly elongated complex in which a globular ''headpiece'' sits at one end of an extended ''stalk'' (Kostelansky et al., 2007) . Our studies are in excellent agreement with their structural and biochemical analyses because they find that yeast ESCRT-I is a 1:1:1:1 complex in which the Mvb12p subunit binds the binary Vps23p/TSG101-Vps37p complex to form the ESCRT-I stalk.
Although our experiments establish that the soluble endogenous ESCRT-I complexes extracted from human cells are 1:1:1:1 complexes of TSG101:VPS28:VPS37: MVB12 (here termed ESCRT-I ''monomers''), several important issues still surround ESCRT-I localization and oligomerization within cells. First, self-association of ESCRT-I and its Vps23p/TSG101 subunit has been reported (Chu et al., 2006; Martin-Serrano et al., 2003; von Schwedler et al., 2003) , and we also observed that a small population of stable ESCRT-I dimers formed under overexpression conditions. Second, a recent immunolocalization study reported that the majority of ESCRT-I is found in close juxtaposition with cellular membranes (Welsch et al., 2006) , whereas all of our analyses were performed on soluble ESCRT-I complexes. We therefore considered the possibility that the Triton detergent used during cell lysis might have altered ESCRT-I oligomerization or membrane association. This was not the case, however, as the soluble endogenous ESCRT-I monomer Figure 7D were quantified to determine changes in protein levels upon MVB12A overexpression (relative to control conditions, lanes 1): Cell-associated Gag protein, 71 ± 8%; cell-associated CA + MA proteins, 11 ± 3%; virion-associated CA + MA proteins, 16 ± 5%. Error bars represent standard deviations in multiple repetitions of the experiment (n = 6). was also the predominant species when cells were lysed in isotonic saline lacking detergent and the soluble ESCRT-I in these crude lysates was analyzed immediately by gel filtration chromatography (data not shown). We therefore conclude that under steady state conditions, human ESCRT-I is a monomer, and any oligomeric or membrane associations must be weak at best. These properties may well change, however, when ESCRT-I is transiently recruited to sites of vesicle formation or virus budding. Indeed, we observe strong endosomal membrane localization of all of the different ESCRT-I subunits, including MVB12A, in the absence of VPS4 ATPase activity, and these membrane-associated multiprotein associations are highly resistant to detergent extraction.
Our data are consistent with the idea that human MVB12 is an important, but not absolutely essential, subunit of human ESCRT-I. Importantly, HIV-1 budding and assembly are perturbed when cellular MVB12 levels are altered, indicating that MVB12 functions in HIV-1 release. Specifically, MVB12 protein depletion caused moderate (2-to 5-fold) decreases in viral infectivity with corresponding increases in the production of electron-dense, amorphous particles. MVB12 protein overexpression inhibited HIV-1 release and infectivity even more severely (12-to 15-fold), and complete inhibition required MVB12 proteins that could bind ESCRT-I and be fully phosphorylated. MVB12 overexpression again altered the phenotype of viral assembly, in this case leading to the accumulation of membrane-tethered, immature particles that remained associated with the cell surface. Remarkably, MVB12 overexpression also dramatically reduced the accumulation of intracellular Gag processing intermediates ( Figure 7A , middle right panel, lanes 2 and 4). TSG101 overexpression also alters the processing pattern of cellassociated Gag, but in that case Gag processing is delayed, resulting in an appreciable buildup of the CA-SP1 and p41 processing intermediates (e.g., Figure 7A , middle right panel, lane 6). Thus, high levels of both MVB12 and TSG101 alter the normal coupling between Gag processing and virus budding, thereby changing the range of cellassociated Gag processing intermediates, but the precise changes in Gag processing are different in the two cases.
Finally, we speculate that MVB12 proteins will also function in the sorting of cellular protein cargoes at the multivesicular body and that they may play a unique role in ESCRT-I function, perhaps in helping to regulate conformational changes, complex release, or other essential ESCRT-I transformations. Evidence in support of a unique regulatory role for MVB12A includes (1) indications that the yeast homolog, Mvb12p, also regulates various different ESCRT-I activities (Chu et al., 2006; Curtiss et al., 2007; Oestreich et al., 2007) , (2) the series of distinctive viral assembly phenotypes that occur in response to altered MVB12 levels, including aberrant virion morphologies and unusual changes in the normal coupling between Gag processing and virus budding, and (3) the extensive number of MVB12A and MVB12B phosphorylation sites, which suggests the possibility of posttranslational regulation. More detailed mechanistic studies of ESCRT-I are clearly warranted, and such studies should be facilitated by the identification of MVB12 as the last remaining core subunit of metazoan ESCRT-I and by the development of methods for producing pure recombinant human ESCRT-I complexes.
EXPERIMENTAL PROCEDURES
Cell Cultures 293T cells and HOS-pBABE-puro cells (generously supplied by Dr. Nathan Landau through the AIDS Reference and Reagent Program, cat. no. 3517) were maintained in DMEM supplemented with 10% FCS. K562 cells were maintained in RPMI-1640 medium supplemented with 10% FCS. To assay HIV-1 production, 5 3 10 5 293T
cells/well (6-well plate) were transfected with 2 mg R9 proviral HIV-1 expression plasmid (Garrus et al., 2001; Swingler et al., 1997) . For immunofluorescence experiments, HOS cells were seeded onto coverslips, cotransfected at 50%-60% confluence, and imaged as described in the caption to Figure S5 .
Expression Plasmids
Expression plasmids used in this study are summarized in Table S3 .
ESCRT-I Complex Purification
For small scale purifications, 293T cells were seeded (3 3 10 6 cells/55 cm 2 dish) and cotransfected with 3 mg each of ESCRT-I expression plasmids using polyethylenimine (25,000 KDa; Polysciences, Warrington, PA) as described (Durocher et al., 2002) . Cells were harvested 48 hr posttransfection by inclubation in 300 ml lysis buffer (LB: 50 mM Tris [pH 7.4], 150 mM NaCl) supplemented with proteinase inhibitor cocktail (Sigma) and 1% Triton X-100. Lysates were clarified by centrifugation (18,0003 g, 10 min, 4 C) and incubated with StrepTactin Sepharose (40 ml slurry, IBA GmbH, Gottingen Germany, 2 hr, 4 C). The matrix was washed 4 times in wash buffer (WB: 20 mM Tris [pH 7.4], 150 mM NaCl) supplemented with 0.1% Triton X-100, and purified ESCRT-I complexes were eluted with 2.5 mM desthiobiotin in WB. Typical yield: 30 mg ESCRT-I. For large-scale preparations (e.g., for analytical ultracentrifugation experiments), this basic procedure was scaled up 200-fold with the following modifications: (1) douncing (1003) was used to promote cell lysis, (2) ESCRT-I complexes were affinity purified on a 5 ml Strep-Tactin Sepharose column (detergent-free LB washes), and (3) affinity purified ESCRT-I complexes were concentrated to 2 ml using a Vivaspin 2 concentrator (Vivascience Ltd., 30,000 MW cutoff) and purified by gel filtration in LB (16/26 Superdex 200 column in LB lacking detergent). Recombinant ESCRT-I complexes eluted in two peaks, a major peak (MW app 280 KDa) and a minor peak (MW app 570 KDa). This procedure typically yielded 1 to 2 mg purified ESCRT-I (major peak).
Gel Filtration Analyses of ESCRT-I Complexes K562 or 293T cells expressing endogenous or exogenous ESCRT-I were suspended in PBS ± 0.1% Triton X-100 and proteinase inhibitor cocktail and lysed by douncing. Lysates were clarified by centrifugation (18,000 3 g, 10 min, 4
) and chromatographed on a calibrated resulting data sets were globally fit using Heteroanalysis software (Cole, 2004) . Analysis of the ESCRT-I dimer is described in Figure S4 .
ESCRT-I Binding Assays
Soluble GST and GST-p6 Gag fusion proteins were expressed in E. coli (Garrus et al., 2001) . Fifty milliliter cultures were pelleted, resuspended in 4 ml binding buffer (150 mM NaCl, 1% NP-40, 10% glycerol, 1 mM DTT, 50 mM Tris [pH 8.0]) and lysed by lysozyme treatment (1.2 mg) and sonication (33). For each binding reaction, protein from 10 ml soluble E. coli extract was captured on 15 ml glutathione-Sepharose slurry (Amersham Biosciences). Recombinant HIS-V5-HRS was expressed in Sf21 insect cells following manufacturer's instructions (BaculoDirect, Invitrogen). Sf21 infected cells were resuspended in LB with 1% Triton X-100 and protease inhibitors, and lysed by dounce homogenization. For each binding reaction, protein from 10 ml soluble Sf21 extracts was captured on 15 ml anti-V5 antibody conjugated resin slurry (Sigma). To assess binding, 0.1 nmol purified recombinant ESCRT-I complex was incubated with 1.0 nmol of immobilized GST-p6 Gag , V5-HRS, or control proteins (1 hr, 4 C in WB supplemented with 0.1% Triton X-100). Unbound ESCRT-I was removed by washing with WB, and bound ESCRT-I proteins were released by boiling in SDS-PAGE loading buffer and analyzed by 12% SDS-PAGE with Coomassie staining or western blotting using rabbit anti-FLAG antibody (1:1000, Sigma).
Antibody Production
Antibodies to affinity-purified recombinant GST-MVB12A and OSF-MVB12B were raised in New Zealand White Rabbits (Covance, Inc.). MVB12A antibodies were affinity purified by binding to recombinant OSF-MVB12A 1-191 , as described (von Schwedler et al., 2003) .
Assays for HIV Release and Infectivity HIV-1 infections were initiated by transfection of the proviral HIV-1 R9 construct, with cell-and virion-associated Gag proteins detected by western blotting and viral titers measured using single-cycle MAGIC assays as described previously (Garrus et al., 2001) . Myc-tagged ESCRT-I proteins were analyzed by western blotting (1:3000 mouse anti-Myc 9E10, Covance).
Electron Microscopy
Procedures for obtaining EM images of free and cell-associated thinsectioned virions were as described previously (von Schwedler et al., 1998) , except that the samples were fixed with 2.5% gluteraldehyde/ 1% paraformaldehyde and dehydrated with an ethanol series.
Supplemental Data
The Supplemental Data include three supplemental tables and six supplemental figures and can be found with this article online at http:// www.cellhostandmicrobe.com/cgi/content/full/2/1/41/DC1/.
